TrialBlood cancer journal2023

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Thomas Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.